The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes

Report on Investigational Drugs

DOI: 10.1007/s12272-011-0721-z

Cite this article as:
Moon, HS., Kim, MK. & Son, MH. Arch. Pharm. Res. (2011) 34: 1041. doi:10.1007/s12272-011-0721-z

Abstract

Glucagon-like peptide-1 (GLP-1) is the main member of the incretin family and stimulates insulin secretion by binding with its specific receptor on pancreatic β-cells. In addition, GLP-1 exerts broad beneficial effects on the glucose regulation by suppressing food intake and delaying stomach emptying. Now, long acting GLP-1 analogs including exenatide and liraglutide have been approved for the treatment of diabetes mellitus type 2, however long-term injection can limit their use for these chronic patients. In this report, the authors provide a review on the development of non-peptide GLP-1 receptor agonists and introduce a novel agonist DA-15864.

Copyright information

© The Pharmaceutical Society of Korea and Springer Netherlands 2011

Authors and Affiliations

  1. 1.Research CenterDong-A Pharm. Co., Ltd.YonginKorea